Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Exelixis, Inc. is a biotechnology company focused on the discovery, development, and commercialization of oncology therapies. The company operates within the biopharmaceutical and life sciences industries, with a primary emphasis on small-molecule targeted cancer treatments. Its core revenue driver is the commercialization of cabozantinib, a tyrosine kinase inhibitor marketed as CABOMETYX and COMETRIQ, which are approved for multiple cancer indications. Exelixis serves oncologists, hospitals, and specialty pharmacies, primarily in regulated healthcare markets.
Founded in 1994, Exelixis initially pursued genomic-based drug discovery before transitioning to a more focused oncology development model in the mid-2000s. The company’s evolution has been marked by strategic licensing, internal R&D investment, and a shift toward building a sustainable commercial-stage biopharmaceutical business. Its competitive positioning is based on deep expertise in kinase biology, a diversified clinical pipeline, and long-term royalty and collaboration revenues from partnered programs.
Business Operations
Exelixis operates through a single reportable segment focused on oncology drug development and commercialization. Revenue is generated from product sales of CABOMETYX in the United States, collaboration and license agreements, and royalties from partners commercializing cabozantinib in international markets. The company retains global development rights for most pipeline assets and maintains internal capabilities across research, clinical development, regulatory affairs, and commercialization.
The company collaborates with multiple global pharmaceutical partners for ex-U.S. commercialization and combination studies. Key partnerships include agreements with Ipsen S.A. for territories outside the U.S. and Japan and Takeda Pharmaceutical Company Limited for Japan. Exelixis also maintains a wholly owned subsidiary, Exelixis Holdings (UK) Limited, which supports international operations and collaborations.
Strategic Position & Investments
Exelixis’s strategic direction centers on expanding the clinical and commercial potential of cabozantinib while advancing a next-generation oncology pipeline. Growth initiatives include label expansion through combination trials, development of novel antibody-drug conjugates and small molecules, and disciplined capital allocation to sustain long-term value creation. The company consistently reinvests operating cash flow into internal R&D rather than large-scale transformational acquisitions.
Notable investments include internal pipeline assets such as zanzalintinib and XB010, as well as earlier-stage programs targeting validated oncology pathways. Exelixis has also made selective equity and licensing investments in emerging oncology technologies, prioritizing assets that complement its expertise in tumor biology and targeted therapies. Data on certain early-stage programs remains limited, and long-term commercial impact is inconclusive based on available public sources.
Geographic Footprint
Exelixis is headquartered in South San Francisco, California, within the United States, and primarily operates in North America. Its commercial presence is strongest in the U.S. oncology market, where it directly markets CABOMETYX. Internationally, the company exerts influence through licensing and collaboration arrangements across Europe, Asia-Pacific, and other global regions.
Through partners, Exelixis-supported products are marketed in major healthcare markets including the European Union, Japan, and parts of Asia and Latin America. While the company does not maintain large-scale commercial infrastructure outside the U.S., its global footprint is extended through regulatory, clinical trial, and royalty-generating activities worldwide.
Leadership & Governance
Exelixis is led by an experienced executive team with deep backgrounds in oncology, drug development, and biopharmaceutical commercialization. The leadership emphasizes disciplined science-driven execution, long-term shareholder value, and sustained investment in innovation. Governance practices align with U.S. public company standards and are overseen by an independent board of directors.
Key executives include:
- Michael M. Morrissey – President and Chief Executive Officer
- Christopher J. Senner – Executive Vice President and Chief Financial Officer
- Dana Aftab, M.D. – Executive Vice President, Product Discovery and Development
- Patrick J. O’Neill – Executive Vice President, Corporate Strategy
- Julie Wood – Senior Vice President, Human Resources
The leadership team’s strategic vision centers on maintaining Exelixis as a leading independent oncology-focused biotechnology company with a balanced approach to innovation, risk management, and capital discipline.